Eli Lilly (LLY) has made significant strides in the biotech sector, especially with its weight-loss and obesity treatment. Particularly, the company's flagship drug,
Zepbound, recently got clearance from the
FDA as the first and only prescription for moderate-to-severe obstructive sleep apnea in adults with obesity – a huge step in battling this global health crisis. The groundbreaking development for Eli Lilly is that the
weight-loss drug shortage has been resolved, suggesting regular supply henceforth. Its drug has also shown superiority over Wegovy, another weight-loss drug. The future prognosis is quite optimistic as Eli Lilly has garnered bullish ratings from institutions such as Citi, Bernstein, and Goldman Sachs, indicating an
improved competitive position in the market. The company also recently announced a partnership with Ro to
expand access to Zepbound. Notably, Eli Lilly's Alzheimer's therapy has received approval in
China, further expanding its global presence. However, amidst the positives, the company has experienced some downsides, such as a rare sales miss for its weight-loss drug.
Eli Lilly LLY News Analytics from Mon, 08 Jul 2024 07:00:00 GMT to Sat, 21 Dec 2024 15:03:30 GMT -
